Mortgage rates today sit near 6% as refi demand jumps and Rocket climbs in premarket
16 January 2026
2 mins read

Mortgage rates today sit near 6% as refi demand jumps and Rocket climbs in premarket

New York, January 16, 2026, 06:34 EST — Premarket

  • U.S. 30-year mortgage rates edged little early Friday, staying close to a three-year low following a steep fall this month.
  • Refinance and purchase demand are reacting, as the MBA reported a jump in applications last week.
  • Shares of Rocket Companies climbed in premarket action as investors weighed the implications of a lower-rate environment.

U.S. mortgage rates stayed close to three-year lows on Friday, with the 30-year fixed rate lingering near 6% in early surveys as the bond market searched for direction. Shares of Rocket Companies climbed 3.4% in premarket trading, reaching $23.44. (Bankrate)

This shift is significant since rates hovering around 6% mark the first genuine decline many buyers have encountered since 2022, despite persistent high home prices. For lenders and housing-related stocks, even a modest fall in borrowing costs can trigger a sharp rise in refinancing activity.

The market has grown unusually sensitive to policy moves. Traders are zeroing in on mortgage-backed bonds and rate forecasts as key indicators of whether this easing will hold through the spring selling season.

Freddie Mac’s latest survey reported the average 30-year fixed mortgage rate at 6.06% for the week ending Jan. 15, down from 6.16% the previous week. The 15-year rate also dropped, settling at 5.38%. According to Freddie Mac Chief Economist Sam Khater, this marks the lowest weekly average in over three years. (GlobeNewswire)

Daily trackers showed a comparable figure. On Thursday, Mortgage News Daily reported the 30-year fixed rate at 6.04%, with the 10-year Treasury yield hovering around 4.17%—a key benchmark lenders often reference when pricing loans. (Mortgage News Daily)

Policy moves sparked fresh momentum. Last week, President Donald Trump ordered the Federal Housing Finance Agency to purchase $200 billion in mortgage bonds from Fannie Mae and Freddie Mac. FHFA Director William Pulte told Reuters the plan kicked off with an initial $3 billion round. Mortgage-backed securities, which are tied to home loan pools, tend to see prices rise when bought up, pushing yields down and helping mortgage rates ease. (Reuters)

Borrowers are reacting swiftly. The Mortgage Bankers Association reported a 28.5% jump in mortgage applications for the week ending Jan. 9, with refinancing climbing 40% and purchase requests rising 16%. Joel Kan, MBA’s vice president and deputy chief economist, attributed the drop in mortgage rates last week to the news of increased MBS purchases. (MBA)

Mortgage originators leaning on volume are seeing a favorable environment. Investors are tracking if reduced rates pull more borrowers in without squeezing lender margins, and if homebuyers respond as spring approaches.

The slide isn’t guaranteed. Mortgage rates could bounce back if Treasury yields climb on stronger inflation numbers or increased government borrowing. Rates might also rise if demand for mortgage bonds eases and spreads widen once more.

The calendar might shake up trading. U.S. stock and bond markets close Monday for Martin Luther King Jr. Day, extending the weekend and likely pushing liquidity into Tuesday. (MarketWatch)

Traders are now eyeing the Federal Reserve’s policy meeting on Jan. 27–28, searching for clues on how long the central bank intends to keep rates unchanged and how it views inflation risks that directly impact long-term yields and mortgage rates. (Federal Reserve)

Stock Market Today

  • Standard BioTools (LAB) Faces Profitability Hurdles Despite Innovative Tech
    January 16, 2026, 8:28 AM EST. Standard BioTools Inc. (NASDAQ: LAB) trades at $1.58 with a 52-week range of $0.92 to $1.88 and a market cap around $607.6 million. The stock sits slightly above the average analyst target of $1.55 but carries a downside risk near 1.9%. The company shows no trailing P/E and a negative forward P/E (-39.50), with no PEG, Price/Book, Price/Sales or EV/EBITDA multiples. Revenue growth has fallen 14.2%; EPS is -0.39 and ROE is -33.26%, alongside a free cash flow deficit of about $188.2 million. Its core technologies - SomaScan, CyTOF, Hyperion and Biomark X9 - underpin its research tools, with licenses from Caltech and Harvard. Analysts rate 1 Buy, 2 Hold. RSI 33.3; 50-day MA $1.39, 200-day MA $1.27. Prospects depend on advancing innovation against financing pressures.
XRP price slips toward $2 as U.S. crypto bill markup is postponed — what traders watch next
Previous Story

XRP price slips toward $2 as U.S. crypto bill markup is postponed — what traders watch next

Oil prices rebound after 4% slide as Iran tension cools, traders eye U.S. stockpiles
Next Story

Oil prices rebound after 4% slide as Iran tension cools, traders eye U.S. stockpiles

Go toTop